Johnson & Johnson Q1 2024 Adj EPS $2.71 Beats $2.64 Estimate, Sales $21.383B Miss $21.398B Estimate
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson (JNJ) reported Q1 2024 adjusted EPS of $2.71, surpassing the $2.64 estimate, marking a 12.45% year-over-year increase. However, their sales of $21.383B slightly missed the $21.398B estimate, though still representing a 2.34% increase from the previous year.
April 16, 2024 | 10:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Q1 2024 earnings beat estimates with an adjusted EPS of $2.71, a 12.45% increase from last year, but sales slightly missed estimates.
The positive earnings beat with a significant year-over-year increase in EPS is likely to be viewed favorably by investors, potentially leading to a short-term positive impact on JNJ's stock price. However, the slight miss in sales estimates could temper some of the positive sentiment, but the overall impact is expected to be positive given the strength in earnings.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100